Name:	us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The total number of new claims filed pertaining to a loss contingency during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

+ Details

Name:	us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of defendants named in a legal action.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyNumberOfDefendants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_OtherCommitmentsAxis=lci_GenusLifeSciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=lci_GovernmentPricingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=lci_KremersUrbanPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=lci_PrivateAntitrustAndConsumerProtectionLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=lci_EndPayerPlaintiffsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=lci_IndirectResellerPlaintiffsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=lci_ShareholderLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Legal, Regulatory Matters and Contingencies (Details) $ in Millions			1 Months Ended		3 Months Ended
	Oct. 15, 2021 USD ($)	May 22, 2019 USD ($)	Aug. 31, 2019 USD ($) product	Nov. 30, 2016 item	Sep. 30, 2021 tranche lawsuit product Distributor	Jun. 30, 2018 product	Oct. 31, 2017 product
Genus Life Sciences
Legal, Regulatory Matters and Contingencies
Litigation settlement payable to other party \| $	$ 1.5
Government Pricing
Legal, Regulatory Matters and Contingencies
Damages sought, value \| $		$ 9.4
Government Pricing \| KUPI
Legal, Regulatory Matters and Contingencies
Damages sought, value \| $			$ 8.1
Private Antitrust and Consumer Protection Litigation
Legal, Regulatory Matters and Contingencies
Number of manufacturers and distributors \| Distributor					30
Number of drugs \| product			135		18		6
Number of Tranches \| tranche					3
Private Antitrust and Consumer Protection Litigation \| Minimum
Legal, Regulatory Matters and Contingencies
Number of lawsuits \| lawsuit					100
End Payer Plaintiffs
Legal, Regulatory Matters and Contingencies
Number of drugs \| product						14
Indirect Reseller Plaintiffs
Legal, Regulatory Matters and Contingencies
Number of drugs \| product						15
Shareholder Litigation
Legal, Regulatory Matters and Contingencies
Number of officers \| item				2